Company intelligence / Profile preview

Kiwi Biosciences

Boston / Cambridge / Somerville*, Massachusetts, United Stateskiwibiosciences.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

The company’s lead product FODZYME® has been launched commercially and certified low-FODMAP by Monash University. It breaks down problematic carbohydrates in foods that trigger gut symptoms in sensitive individuals. Clinical results are not detailed publicly but the product has achieved commercial status and certification from a leading academic group.[1][3] Pipeline includes further enzyme formulations targeting additional FODMAP subtypes.

Therapeutic areas: Gastroenterology
Modalities: Enzymes (novel patent-pending enzyme blends)
Industry: Biotech

Drug pipeline

1 asset

FODZYME

Unknown

Partnerships

Monash University certification of lead product as low-FODMAPY Combinator accelerator support

Beyond the preview

Go deeper on Kiwi Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kiwi Biosciences.

Explore the full profile